In vivo PET studies of the dopamine D2 receptors in rhesus monkeys with long‐term MPTP‐induced parkinsonism

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Synapse

• Publication date

  2000-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/1098-2396(200011)38:2<105::AID-SYN1>3.0.CO;2-SPMID 11018784
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dopamine receptors in the parkinsonian brain

  2005cited by this paper
• L-DOPA reverses the elevated density of D2 dopamine receptors in Parkinson's diseased striatum

  2005cited by this paper
• 6-18F-L-DOPA imaging of the dopamine neostriatal system in normal and clinically normal MPTP-treated rhesus monkeys

  2004cited by this paper
• Spatial memory improvement by levodopa in parkinsonian MPTP-treated monkeys

  1999cited by this paper
• Parallel loss of presynaptic and postsynaptic dopamine markers in normal aging

  1998cited by this paper
• Evidence for striatal dopamine release during a video game

  1998cited by this paper
• Effects of NMDA antagonism on striatal dopamine release in healthy subjects: Application of a novel PET approach

  1998cited by this paper
• 6‐[18F]fluoro‐L‐DOPA PET studies of the turnover of dopamine in MPTP‐induced parkinsonism in monkeys

  1998cited by this paper
• Density and Affinity of D1 and D2 Dopamine (DA) Receptors in Monkey: In Vivo PET studies with [11C]SCH23390 and [11C]Raclopride

  1998cited by this paper
• Quantification of Amphetamine-Induced Changes in [11C]Raclopride Binding with Continuous Infusion

  1997cited by this paper
• Distinct binding patterns of [3H]raclopride and [3H]spiperone at dopamine D2 receptors in vivo in rat brain. Implications for pet studies.

  1997cited by this paper
• Parametric imaging of ligand-receptor binding in PET using a simplified reference region model.

  1997cited by this paper
• Comparison of Methods for Analysis of Clinical [11C]Raclopride Studies

  1996cited by this paper
• Simplified reference tissue model for PET receptor studies.

  1996cited by this paper
• Dynamic Changes in Striatal Dopamine D2 and D3 Receptor Protein and mRNA in Response to 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Denervation in Baboons

  1996cited by this paper
• Levodopa‐induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET

  1996cited by this paper
• Iodine-123-iodobenzamide binding in parkinsonism: reduction by dopamine agonists but not L-Dopa.

  1996cited by this paper
• Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data

  1996cited by this paper
• Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.

  1995cited by this paper
• Time dependent changes in DA uptake sites, D1 and D2 receptor binding and mRNA after 6-OHDA lesions of the medial forebrain bundle in the rat brain.

  1995cited by this paper
• Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride.

  1995cited by this paper
• Positron emission tomographic evidence for progression of human MPTP‐induced dopaminergic lesions

  1994cited by this paper
• [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease

  1994cited by this paper
• Decrease in Human Striatal Dopamine D2 Receptor Density with Age: A PET Study with [11C]Raclopride

  1993cited by this paper
• Dopamine receptors status after unilateral nigral 6-OHDA lesion. Autoradiographic and in situ hybridization study in the rat brain.

  1993cited by this paper
• Asymmetrical pre-synaptic and post-synpatic changes in the striatal dopamine projection in dopa naïve parkinsonism. Diagnostic implications of the D2 receptor status.

  1993cited by this paper
• Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism.

  1993cited by this paper
• Striatal binding of the PET ligand 11C‐raclopride is altered by drugs that modify synaptic dopamine levels

  1993cited by this paper
• The causalgia-dystonia syndrome.

  1993cited by this paper
• Correlation of striatal fluorodopa uptake in the MPTP Monkey with dopaminergic indices

  1993cited by this paper
• The cloned dopamine D2 receptor reveals different densities for dopamine receptor antagonist ligands. Implications for human brain positron emission tomography.

  1992cited by this paper
• Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C‐raclopride and positron emission tomography

  1992cited by this paper
• Regioselective radiofluorodestannylation with [18F]F2 and [18F]CH3COOF: a high yield synthesis of 6-[18F]Fluoro-L-dopa.

  1992cited by this paper
• Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease.

  1991cited by this paper
• Dopamine receptor changes in untreated and (+)-PHNO-treated MPTP parkinsonian primates.

  1991cited by this paper
• Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. I. 6-OHDA lesions of ascending mesencephalic dopaminergic pathways in the rat.

  1990cited by this paper
• Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease

  1990cited by this paper
• Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. II. Unilateral intra-carotid infusion of MPTP in the monkey (Macaca fascicularis).

  1990cited by this paper
• Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin-D28K.

  1990cited by this paper
• Subdivisional involvement of nigrostriatal loop in idiopathic parkinson's disease and striatonigral degeneration

  1989cited by this paper
• Unilateral MPTP lesion in a rhesus monkey: effects on the striatal dopaminergic system measured in vivo with PET using various novel tracers.

  1988cited by this paper
• Relation between brain dopamine loss and D2 dopamine receptor density in MPTP monkeys.

  1988cited by this paper
• Dopamine receptors in Parkinson's disease.

  1988cited by this paper
• D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy.

  1988cited by this paper
• Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications.

  1988cited by this paper
• Raclopride, a new selective ligand for the dopamine-D2 receptors.

  1988cited by this paper
• Dopamine receptor properties in Parkinson's disease and Huntington's chorea evaluated by positron emission tomography using 11C‐N‐methyl‐spiperone

  1987cited by this paper
• MPTP‐induced up‐regulation of in vivo dopaminergic radioligand‐receptor binding in humans

  1987cited by this paper
• No D2 receptor increase in PET study of schizophrenia.

  1987cited by this paper
• Dopamine D2 receptor density remains constant in treated Parkinson's disease

  1986cited by this paper
• Hemiparkinsonism in a monkey after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is associated with regional ipsilateral changes in striatal dopamine D-2 receptor density.

  1986cited by this paper
• Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain.

  1985cited by this paper
• Changes of the striatal 3H-spiperone binding 3-6 weeks after nigrostriatal denervation and after two years.

  1985cited by this paper
• Brain neurotransmitter changes in Parkinson's disease

  1981cited by this paper
• Pathology of Parkinson's disease

  1981cited by this paper

• Relation between microPET imaging and rotational behavior in a parkinsonian rat model induced by medial forebrain bundle axotomy.

  2014cites this paper
• Animal Models of Movement Disorders

  2012influential citation
• Antiparkinsonian Mechanism of Electroconvulsive Therapy in MPTP-Lesioned Non-Human Primates

  2012cites this paper
• The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys

  2011cites this paper
• Electroconvulsive Therapy Alters Dopamine Signaling in the Striatum of Non-human Primates

  2011cites this paper
• Advances in imaging in Parkinson's disease.

  2011cites this paper
• Quantification of Brain Function and Neurotransmission System In Vivo by Positron Emission Tomography: A Review of Technical Aspects and Practical Considerations in Preclinical Research

  2011cites this paper
• Dynamic changes of striatal dopamine D2 receptor binding at later stages after unilateral lesions of the medial forebrain bundle in Parkinsonian rat models.

  2011cites this paper
• Different striatal D2-like receptor function in an early stage after unilateral striatal lesion and medial forebrain bundle lesion in rats.

  2010cites this paper
• EFECTO DE LA ADMINISTRACIÓN CRÓNICA DE LEVODOPA SOBRE LA ACTIVIDAD FUNCIONAL DE LA VÍA NIGROESTRIADA EN MACACOS CON PARKINSONISMO INDUCIDO POR MPTP

  2010cites this paper
• Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease?

  2009cites this paper
• Radiotracer imaging in PD: value of in vivo presynaptic dopaminergic measures in animal models and human disease

  2009cites this paper
• Mood, memory and movement: an age-related neurodegenerative complex?

  2008cites this paper
• The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson’s disease

  2008cites this paper
• Estimation of D2-like Receptor Occupancy by Dopamine in the Putamen of Hemiparkinsonian Monkeys

  2008cites this paper
• Progressive changes of pre‐ and post‐synaptic dopaminergic biomarkers in conscious MPTP‐treated cynomolgus monkeys measured by positronemission tomography

  2007cites this paper
• Animal Models of Neurodegenerative Disease: Insights from In vivo Imaging Studies

  2007cites this paper
• Electroconvulsive shock enhances striatal dopamine D1 and D3 receptor binding and improves motor performance in 6-OHDA-lesioned rats.

  2007cites this paper
• Effect of age on markers for monoaminergic neurons of normal and MPTP-lesioned rhesus monkeys: A multi-tracer PET study

  2006cites this paper
• Sequential versus Nonsequential Measurement of Density and Affinity of Dopamine D2 Receptors with [11C]Raclopride: 2: Effects of DAT Inhibitors

  2006cites this paper
• Psychosis pathways converge via D2High dopamine receptors

  2006cites this paper
• CHAPTER B2 – MPTP-Induced Nigrostriatal Injury in Nonhuman Primates

  2005cites this paper
• Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism.

  2004cites this paper
• PET imaging of implanted human retinal pigment epithelial cells in the MPTP-induced primate model of Parkinson's disease.

  2004cites this paper
• Positron emission tomography receptor assay with multiple ligand concentrations: an equilibrium approach.

  2004cites this paper
• Evaluation of animal models of Parkinson's disease for neuroprotective strategies.

  2004cites this paper
• Gradients of dopamine D1- and D2/3-binding sites in the basal ganglia of pig and monkey measured by PET

  2004cites this paper
• Quantitative Assay Development for PET

  2004cites this paper
• Functional Brain Imaging and Large Animal Research

  2004cites this paper
• Raclopride studies of dopamine release: dependence on presynaptic integrity.

  2003cites this paper
• Effects of acute nicotine on hemodynamics and binding of [11C]raclopride to dopamine D2, 3 receptors in pig brain

  2003cites this paper
• Mapping of brain function after MPTP-induced neurotoxicity in a primate Parkinson's disease model

  2003cites this paper
• In Vivo Measurement of Receptor Density and Affinity: Comparison of the Routine Sequential Method with a Nonsequential Method in Studies of Dopamine D2 Receptors with [11C]Raclopride

  2003cites this paper
• An increase of sigma receptors in the aged monkey brain.

  2003cites this paper
• Mechanism of new antipsychotic medications: occupancy is not just antagonism.

  2003cites this paper
• Kinetics of the uptake and distribution of the dopamine D(2,3) agonist (R)-N-[1-(11)C]n-propylnorapomorphine in brain of healthy and MPTP-treated Göttingen miniature pigs.

  2003cites this paper
• Sequential Versus Nonsequential Measurement of Density and Affinity of Dopamine D2 Receptors with [11C]raclopride: Effect of Methamphetamine

  2003cites this paper
• Functional imaging of the dopamine system: in vivo evaluation of dopamine deficiency and restoration.

  2002cites this paper
• Density and affinity of the dopamine D2 receptors in aged symptomatic and asymptomatic MPTP‐treated monkeys: PET studies with [11C]raclopride

  2002influential citation
• In vivo PET studies of the dopamine D1 receptors in rhesus monkeys with long‐term MPTP‐induced Parkinsonism

  2002influential citation
• In Vivo Receptor Assay with Multiple Ligand Concentrations: An Equilibrium Approach

  2002cites this paper
• Evaluation of Early and Prolonged Effects of Acute Neurotoxicity and Neuroprotection Using Novel Functional Imaging Techniques

  2002cites this paper
• Shor tCommunication I nViv oPE TStudie so fth eDopamin eD1 Receptor sI nRhesu sMonkey sWith Long-Ter mMPTP-Induce dParkinsonism

  2002cites this paper
• PET studies in the MPTP model of Parkinson's disease.

  2001cites this paper
• Evaluation of neurotoxicity of TIQ and MPTP and of parkinsonism‐preventing effect of 1‐MeTIQ by in vivo measurement of pre‐synaptic dopamine transporters and post‐synaptic dopamine D2 receptors in the mouse striatum

  2001cites this paper